PPLPHARMA Piramal Pharma Q3 FY25 results (Oct–Dec 2024) and concall
Piramal Pharma delivered a steady performance in Q3 FY25, characterized by strong growth in its CDMO and Consumer Healthcare segments. While the development side of the CDMO business remains subdued due to the global biotech funding environment, commercial manufacturing is providing robust momentum. Management remains committed to its long-term 'FY30' targets while navigating short-term tax rate volatility and supply constraints in specific injectable portfolios.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 2,242 | 2,204 |
| EBITDA | 342 | 338 |
| Net profit | 23 | 4 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
